BGLC vs. MRAI, ENZ, BRTX, MGRX, OTRK, SSY, DHAC, VSEE, ATIP, and ACON
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Marpai (MRAI), Enzo Biochem (ENZ), BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), Ontrak (OTRK), SunLink Health Systems (SSY), Digital Health Acquisition (DHAC), Vsee Health (VSEE), ATI Physical Therapy (ATIP), and Aclarion (ACON). These companies are all part of the "healthcare" industry.
BioNexus Gene Lab vs. Its Competitors
Marpai (NASDAQ:MRAI) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
BioNexus Gene Lab has lower revenue, but higher earnings than Marpai.
Marpai has a beta of 4.8, suggesting that its share price is 380% more volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 5.6, suggesting that its share price is 460% more volatile than the S&P 500.
BioNexus Gene Lab has a net margin of -10.17% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.
In the previous week, BioNexus Gene Lab had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Marpai. BioNexus Gene Lab's average media sentiment score of 1.87 beat Marpai's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.
49.8% of Marpai shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 61.3% of Marpai shares are held by insiders. Comparatively, 0.7% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Marpai received 2 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users. Likewise, 66.67% of users gave Marpai an outperform vote while only 0.00% of users gave BioNexus Gene Lab an outperform vote.
Summary
Marpai beats BioNexus Gene Lab on 7 of the 13 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
This page (NASDAQ:BGLC) was last updated on 6/13/2025 by MarketBeat.com Staff
